Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma AS's revenue per share for the
three
months ended in Jun. 2026 was $9.78.
Zealand Pharma AS's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $10.11.
Warning Sign:
Zealand Pharma AS revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Zealand Pharma AS was -48.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 285.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 50.30% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 6.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Zealand Pharma AS's Revenue per Share or its related term are showing as below:
ZLDPF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -60.7 Med: 4.4 Max: 285.3
Current: 285.3
During the past 13 years, Zealand Pharma AS's highest 3-Year average Revenue Per Share Growth Rate was 285.30% per year. The lowest was -60.70% per year. And the median was 4.40% per year.
ZLDPF's 3-Year Revenue Growth Rate is ranked better than 97.91% of 767
companies
in the Biotechnology industry
Industry Median: 3.3
vs ZLDPF: 285.30
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Zealand Pharma AS Revenue per Share Related Terms
Zealand Pharma AS Revenue per Share Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDPF vs VRTX, REGN, MRNA: Revenue per Share Comparison
For the Biotechnology subindustry, Zealand Pharma AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Zealand Pharma AS's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a Revenue per Share of $10.11 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #16 out of 767 companies in the Biotechnology industry, placing it in the top 2.1%.
Is Zealand Pharma AS's Revenue per Share too high?
Zealand Pharma AS's current Revenue per Share is $10.11. The Biotechnology industry median Revenue per Share is 3.30. Zealand Pharma AS's value of $10.11 is 206.4% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #16 out of 767 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #16 out of 767 companies for Revenue per Share. This places Zealand Pharma AS in the top 2% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.30. Zealand Pharma AS's value of $10.11 is 206.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.30, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Revenue per Share of $10.11 is 206.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Revenue per Share is $10.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $2,510.68, compared to a current price of $43.00 — trading 98.3% below its estimated fair value. The current Revenue per Share is $10.11 and 206.4% above the Biotechnology industry median of 3.30. Zealand Pharma AS's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Revenue per Share is $10.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $43.00 is trading 98.3% below its estimated GF Value™ of $2,510.68.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Revenue per Share: $10.11
GF Value™: $2,510.68 vs. price of $43.00 (98.3% below fair value)
Industry Position: 206.4% above the Biotechnology median (#16 of 767)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
63GF Score
Get the complete analysis for ZLDPF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
